Chief executive Witty steps back from AstraZeneca battle, declairing caution on mega deals

Transactions worth $140bn so far this year include asset swap between Novartis and GlaxoSmithKline

London Briefing: major drug shares in UK soar on talk of mergers, acquisitions and asset swaps

The prediction does not take into account the negative impact of a strengthening pound

Firm also plans to stop tying compensation of sales reps to prescriptions written

China sales slump 61% as doctors shun GSK products

As its Q2 figures are posted, the pharma giant can’t seem to apologise enough